These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 23807252

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies: an open-lable, multicenter, observational trial in a Chinese cohort.
    Cheng S, Zhou JF, Zou P, Huang XJ, Jin J, Shen ZX.
    Chin Med J (Engl); 2011 Nov; 124(22):3670-5. PubMed ID: 22340222
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.
    Jeong SH, Kim DY, Jang JH, Mun YC, Choi CW, Kim SH, Kim JS, Park JS.
    Ann Hematol; 2016 Jan; 95(2):337-44. PubMed ID: 26596974
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea.
    Kim SJ, Cheong JW, Min YH, Choi YJ, Lee DG, Lee JH, Yang DH, Lee SM, Kim SH, Kim YS, Kwak JY, Park J, Kim JY, Kim HG, Kim BS, Ryoo HM, Jang JH, Kim MK, Kang HJ, Cho IS, Mun YC, Jo DY, Kim HY, Park BB, Kim JS.
    J Korean Med Sci; 2014 Jan; 29(1):61-8. PubMed ID: 24431907
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.
    Kim JS, Cheong JW, Shin HJ, Lee JW, Lee JH, Yang DH, Lee WS, Kim H, Park JS, Kim SH, Kim YS, Kwak JY, Chae YS, Park J, Do YR, Min YH.
    Yonsei Med J; 2014 Jan; 55(1):9-18. PubMed ID: 24339281
    [Abstract] [Full Text] [Related]

  • 9. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole.
    Kanda Y, Kami M, Matsuyama T, Mitani K, Chiba S, Yazaki Y, Hirai H.
    Hematol Oncol; 1998 Mar; 16(1):33-7. PubMed ID: 9821410
    [Abstract] [Full Text] [Related]

  • 10. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C, Pasold R, Wolf HH, Hänel M, Dölken G, Junghanss C, Andreesen R, Bertz H, Itraconazole Research Group of Germany.
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
    Schuler U, Bammer S, Aulitzky WE, Binder C, Böhme A, Egerer G, Sandherr M, Schwerdtfeger R, Silling G, Wandt H, Glasmacher A, Ehninger G.
    Onkologie; 2007 Apr; 30(4):185-91. PubMed ID: 17396041
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.
    Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K.
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1887-93. PubMed ID: 10858349
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Sequential intravenous and oral itraconazole in treatment of invasive fungal infection in hematological diseases].
    Group of Itraconazole Multi-Central Clinical TrialDepartment of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University Medical College, Shanghai 200025, China. rjchenyu@tom.com, Chen Y, Shen ZX.
    Zhonghua Nei Ke Za Zhi; 2008 Dec; 47(12):1026-9. PubMed ID: 19134310
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A, Prentice AG.
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.